The munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index consists of 8 constituents in each of the munKNEE Pure-Play Marijuana Drug Stocks Index and the munKNEE Pure-Play Psychedelic Compounds-Based Drug Stocks Index. Which has performed best YTD? This article has the answers. Here are the details:

One hundred clinical-stage psychedelic drug stocks now trade on North American stock exchanges. 60 of the stocks research the treatment of a variety of mental illnesses based on the use of 9 different psychedelic substances (read Psychedelic Drug Stocks: All You Need To Know): psilocybin (AKA "magic" mushrooms), psilocybin truffles (AKA "magic" truffles), ketamine (AKA "the date rape drug"), DMT, Ibogaine, LSD (AKA "acid"), MDMA (AKA "ecstasy"), mescaline (AKA "peyote) and 5-MeO-DMT (AKA "toad"); 40 research the treatment of illnesses based on the use of THC marijuana (read Marijuana Drug Stocks: All You Need To Know).

The criteria for inclusion in the munKNEE Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index is that its constituents have market capitalizations in excess of $50M but less than $500M and only 16 of the 100 psychedelic drug stocks meet that criteria. The remaining 84 stocks in the Index have market caps below $50M or are above $500M. The latter include ATAI, Compass Pathways, Mind Medicine, and GH Resources and they are not included in the index given their very large market caps and high share prices which would have dominated the index's performance.

The Marijuana-Based Drug Stocks Category

The 8 marijuana-based clinical-stage stocks in munKNEE's Pure-Play Marijuana Drug Stocks Index

• are DOWN -6.8% month-to-date (MTD) and 
• are now DOWN -15.6% YTD,
• ranged in price from $0.03/share to $4.09/share (an average of $1.08/share) as of Friday,
• have an average market capitalization of $104M and

Those that have changed in price by +/- 5% MTD are presented below in descending order with YTD percentage movement in brackets:

1. Tetro Bio (TBPMF): is UP +9.5% MTD and is now UP +53.3% YTD
2. Zynerba (ZYNE): is DOWN -7.3% MTD and is now DOWN -23.9% YTD
   • Q2 financial results slightly missed analyst estimates.
3. Enveric (ENVB): is DOWN -8.9% MTD and is now DOWN -59.2% YTD
4. Corbus (CRBP): is DOWN -9.5% MTD and is now unchanged in price YTD
   • Q2 financial results slightly missed analyst estimates.
5. Revive (RVVTF): is DOWN -17.9% MTD and is now DOWN -34.7% YTD.
   • announced that its management is unaware of any undisclosed material information relating to the Company that may be contributing to the recent increase in its trading activity.

The Psychedelic Compounds-Based Drug Stocks Category

The 8 psychedelic-based clinical-stage stocks in munKNEE's Pure-Play Psychedelic Compounds-Based Drug Stocks Index

• are DOWN -0.9% MTD and are now UP +56.2% YTD
• range in price from $0.21/share to $5.75/share (an average of $1.82/share) as of last Friday,
• an average market capitalization of $200M and

Those that have changed in price by +/- 5% MTD are presented below in descending order with YTD percentage movement in brackets:

1. Awakn Life (AWKNF): is UP +11.8% MTD and is now DOWN -3.2% since beginning to trade on June 23rd
   • Announced that it has begun trading on the OTCQB Venture Market ("OTCQB") under the ticker symbol "AWKNF".
2. Mydecine (MYCOF): is UP +7.9% MTD and is now UP +17.1% YTD
3. Numinus (LKYSF): is DOWN -5.1% MTD and is now DOWN -11.9% YTD
4. Small Pharma (DMTTF): is DOWN -15.8% MTD and is now DOWN -15.9% since being listed on June 3rd.

In Summary

• our Pure-Play Marijuana & Psychedelic Compounds-Based Drug Stocks Index is DOWN -0.5% MTD but is UP +20.3% YTD
  • our Marijuana-Based Drug Stocks Index is DOWN -6.8% MTD and is now DOWN -15.6% YTD
  • our Psychedelic Compounds-Based Index is DOWN -0.9% MTD but is still UP +56.2% YTD

The answer to the opening question as to "Which category has performed best MTD?" the answer is the munKNEE Psychedelic Compounds-Based Index which is DOWN -0.9% vs. -6.8% for the munKNEE Marijuana-Based Drug Stocks Index and +56.2% vs. -15.6% YTD respectively.

For those interested, my previous article, Canadian Vs. American Pot Stock Performances Last Week, asked a similar question about the performance of the two sub-categories in the munKNEE  Pure-Play "Seed-to-Sale" Pot Stocks Index, Canadian Pure-Play Licensed Producers (LPs) Pot Stock Index and the Pure-Play American Multi-State Operators (MSOs) Pot Stock Index. We answered the questions "did the LP or MSO sub-category perform better last week? Which sub-category has performed best YTD?"  here.

(All currency amounts are in U.S. dollars. Go here to convert to another currency.)